OncoMatch/Clinical Trials/NCT05623982
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Is NCT05623982 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GNC-038 for non-hodgkin's lymphoma.
Treatment: GNC-038 — To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
Patients with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL)
Cannot have received: autologous hematopoietic stem cell transplantation
Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before initiating GNC-038 treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
Cannot have received: CAR-T cell therapy
CAR-T therapy within 12 weeks before initiating GNC-038 treatment
Cannot have received: radiation therapy
Radiotherapy within 4 weeks before initiating GNC-038 treatment
Cannot have received: chemotherapy
Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment
Cannot have received: small-molecule targeted therapy
Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment
Cannot have received: investigational drug
Use of any other investigational drug in a clinical trial within 4 weeks or 5 half-lives before the first dose of this study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify